Carcinosarcoma (adenocarcinoma, neuroendocrine carcinoma, undifferentiated carcinoma and chondrosarcoma) of the gallbladder

Mochizuki, Kazuki; Hata, Hideo; Naitou, Keiichi; Kondo, Tetsuo

doi:10.1007/s12328-019-01012-7

Cited by 15 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gallbladder cancer is the most common and aggressive biliary tract malignancy with the shortest median survival time. The first case of a carcinosarcoma of the gallbladder (CSGB) was reported by Landsteiner in 1907 [ 1 ]. Up to now less than 100 Cases have been reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

“…According to Zhang’s et al meta-analysis of 68 cases, the age of the patients ranged from 45 to 91 years, with a mean of 68. As for female prevalence, it was presented with a sex ratio of 2,7 [ 1 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, among resected cases, 31% represents the overall 5-year survival rate while 8.3% stands for the percentage of people who died in hospitals. As it is apparent, it is likely that the overall survival rate is low because two thirds of the patients had severe invasion and/or damage to other organs [ 1 ].…”

Section: Discussionmentioning

confidence: 99%

“…Its carcinogenesis follows a progression through a metaplasia–dysplasia–carcinoma sequence. It is usually detected at an advanced stage mainly due to the ambiguity of its clinical presentation, its aggressive biology and its anatomic proximity to the liver [ 1 ]. In this article, we report the case of 61 years old male patient, who was brought to our hospital for a suspicious vesicular mass whose surgical exploration revealed a large locally advanced vesicular mass.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Surgical management of gallbladder carcinosarcoma: A case report and review of the Literature

Madani

Jabi

Achraf

et al. 2020

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

Highlights Gallbladder carcinosarcoma is a rare disease: The first case of a carcinosarcoma of the gallbladder (CSGB) was reported by Landsteiner in 1907. Up to now less than 100 Cases have been reported in the literature. Non-specific signs: the clinical (abdominal pain, weight loss and jaundice, biological (including inflammatory sign, hepatic result), and radiological signs are nonspecific of gallbladder carcinosarcoma, The final diagnosis is anatomopathological of the specimen. The diagnosis is delayed: Because of the nonspecific symptoms, a delayed diagnosis is generally associated with CSGB. Only 54 cases have undergone surgical resection as a treatment. Surgical treatment remains the only cure for gallbladder carcinosarcoma: Chemotherapy and/or radiotherapy’s roles, they remain unclear because of the limited number of cases described in the literature, as chemotherapy has shown no a significant benefit in terms of morbidity or mortality. Prognosis: The prognosis of this disease is normally poor. Most cases present with locally advanced disease and metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Surgical management of gallbladder carcinosarcoma: A case report and review of the Literature

Madani

Jabi

Achraf

et al. 2020

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

show abstract

“…328 However, in GBC, the expression of KIT was elevated. 329 At present, at least 16 KIT inhibitors are available for the blockade of its activity elevated in various types of cancers, including leukemia, prostate cancer, gastrointestinal stromal tumor, and renal carcinoma. 330 – 333 Typical therapeutic blocking agents employed to target KIT include cabozantinib, dovitinib, masitinib, and pazopanib.…”

Section: Targeted Therapy Of Gbcmentioning

confidence: 99%

Overview of current targeted therapy in gallbladder cancer

Song

et al. 2020

Sig Transduct Target Ther

112

View full text Add to dashboard Cite

Gallbladder cancer (GBC) is rare, but is the most malignant type of biliary tract tumor. Unfortunately, only a small population of cancer patients is acceptable for the surgical resection, the current effective regimen; thus, the high mortality rate has been static for decades. To substantially circumvent the stagnant scenario, a number of therapeutic approaches owing to the creation of advanced technologic measures (e.g., next-generation sequencing, transcriptomics, proteomics) have been intensively innovated, which include targeted therapy, immunotherapy, and nanoparticle-based delivery systems. In the current review, we primarily focus on the targeted therapy capable of specifically inhibiting individual key molecules that govern aberrant signaling cascades in GBC. Global clinical trials of targeted therapy in GBC are updated and may offer great value for novel pathologic and therapeutic insights of this deadly disease, ultimately improving the efficacy of treatment.

show abstract

Targeted Therapy: Molecular Pathology and Targets of Gallbladder Cancer

Bhasker

Ahmad

2023

Gallbladder Cancer

View full text Add to dashboard Cite

Carcinosarcoma (adenocarcinoma, neuroendocrine carcinoma, undifferentiated carcinoma and chondrosarcoma) of the gallbladder

Cited by 15 publications

References 21 publications

Surgical management of gallbladder carcinosarcoma: A case report and review of the Literature

Surgical management of gallbladder carcinosarcoma: A case report and review of the Literature

Overview of current targeted therapy in gallbladder cancer

Targeted Therapy: Molecular Pathology and Targets of Gallbladder Cancer

Contact Info

Product

Resources

About